Design of a modified mouse protein with ligand binding properties of its human analog by molecular dynamics simulations: The case of C3 inhibition by compstatin

Proteins: Structure, Function and Bioinformatics

Volumn 79, Issue 11, 2011, Pages 3166-3179

  Tamamis, Phanourios ^a,b,c   Pierou, Panayiota ^a   Mytidou, Chrystalla ^a   Floudas, Christodoulos A ^b   Morikis, Dimitrios ^c   Archontis, Georgios ^a  

^a UNIVERSITY OF CYPRUS   (Cyprus)

^b Princeton University   (United States)

^c University of California Riverside   (United States)

Author keywords

C3 inhibitors; Complement system; Compstatin analogs; Innate immune response; Molecular dynamics

Indexed keywords

COMPLEMENT COMPONENT C3; COMPSTATIN; PEPTIDE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; HUMAN; LIGAND BINDING; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN INTERACTION; PROTEIN STRUCTURE;

AMINO ACID SEQUENCE; ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT C3; CRYSTALLOGRAPHY, X-RAY; HUMANS; LIGANDS; MICE; MICE, TRANSGENIC; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; PEPTIDES; PEPTIDES, CYCLIC; PROTEIN BINDING; PROTEIN CONFORMATION; SEQUENCE ALIGNMENT;

ANIMALIA; MAMMALIA; MUS MUSCULUS; PRIMATES; RATTUS;

EID: 80053938364     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.23149     Document Type: Article

References (46)

1. Muller-Eberhard HJ. Complement-chemistry and pathways. In: Gallin JI, Goldstein IM, Synderman R, editors. Inflammation: basic principles and clinical correlates, 2nd ed. New York: Raven Press; 2002. pp 21-54.
2. Anderson DH, Radeke MJ, Gallo NB, Chapin EA, Johnson PT, Curletti CR, Hancox LS, Hu J, Ebright JN, Malek G, Hauser MA, Rickman CB, Bok D, Hageman GS, Johnson LV. The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog Retin Eye Res 2010; 29: 95-112.
3. Sahu A, Lambris JD. Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics. Immunopharmacology 2000; 49: 133-148.
4. Janssen BJC, Halff EF, Lambris JD, Gros P. Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition. J Biochem 2007; 282: 29241-29247.
5. Ricklin D, Lambris JD. Compstatin: A complement inhibitor on its way to clinical application. Adv Exp Med Biol 2008; 632: 273-292.
6. Morikis D, Lambris JD. Structure, dynamics, activity and function of compstatin and design of more potent analogs. In: Morikis D, Lambris JD, editors. Structural biology of the complement system. Boca Raton, FL: CRC Press/Taylor & Francis Group; 2005. pp 317-340.
7. Soulika AM, Holl MCH, Sfyroera G, Sahu A, Lambris JD. Compstatin inhibits complement activation by binding to the β-chain of complement factor 3. Mol Immunol 2006; 43: 2023-2029.
8. Sahu A, Ray BK, Lambris JD. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. J Immunol 1996; 157: 884-891.
9. Morikis D, Assa-Munt N, Sahu A, Lambris JD. Solution structure of compstatin, a potent complement inhibitor. Protein Sci 1998; 7: 619-627.
10. Klepeis JL, Floudas CA, Morikis D, Lambris JD. Predicting peptide structures using NMR data and deterministic global optimization. J Comput Chem 1999; 20: 1354-1370.
11. Sahu A, Soulika A, Morikis D, Spruce L, Moore WT, Lambris JD. Binding kinetics, structure-activity relationship, and biotransformation of the complement inhibitor compstatin. J Immunol 2000; 165: 2491-2499.
12. Morikis D, Roy M, Sahu A, Troganis A, Jennings PA, Tsokos GC, Lambris JD. The structural basis of compstatin activity examined by structure-function-based design of peptide analogs and NMR. J Biol Chem 2002; 277: 14942-14953.
13. Morikis D, Lambris JD. Structural aspects and design of low-molecular-mass complement inhibitors. Biochem Soc Trans 2002; 30: 1026-1036.
14. Mallik B, Lambris JD, Morikis D. Conformational interconversion in compstatin probed with molecular dynamics simulations. Proteins 2003; 52: 130-141.
15. Tamamis P, Skourtis S, Morikis D, Lambris JD, Archontis G. Conformational analysis of compstatin analogues with molecular dynamics simulations in explicit water. J Mol Graph Model 2007; 26: 571-580.
16. Klepeis J, Floudas CA, Morikis D, Tsokos CG, Argyropoulos E, Spruce L, Lambris JD. Integrated computational and experimental approach for lead optimization and design of compstatin variants with improved activity. J Am Chem Soc 2003; 125: 8422-8423.
17. Soulika AM, Morikis D, Sarrias MR, Roy M, Spruce LA, Sahu A, Lambris JD. Studies of structure-activity relations of complement inhibitor compstatin. J Immunol 2003; 170: 1881-1890.
18. Morikis D, Soulika AM, Mallik B, Klepeis JL, Floudas CA, Lambris JD. Improvement of the anti-C3 activity of compstatin using rational and combinatorial approaches. Biochem Soc Trans 2004; 32: 28-32.
19. Mallik B, Katragadda M, Spruce LA, Carafides C, Tsokos CG, Morikis D, Lambris JD. Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem 2005; 48: 274-286.
20. Mallik B, Morikis D. Development of a quasi-dynamic pharmacophore model for anti-complement peptide analogues. J Am Chem Soc 2005; 127: 10967-10976.
21. Chiu TL, Mulakala C, Lambris JD, Kaznessis YN. Development of a new pharmacophore model that discriminates active compstatin analogs. Chem Biol Drug Des 2008; 72: 249-256.
22. Morikis D, Lambris JD. Structural aspects and design of low-molecular-mass complement inhibitors. Biochem Soc Trans 2002; 30: 1026-1036.
23. Klepeis JL, Floudas CA, Morikis D, Tsokos CG, Lambris JD. Design of peptide analogs with improved activity using a de novo protein design approach. Ind Eng Chem Res 2004; 43: 3817-3826.
24. Holland MCH, Morikis D, Lambris JD. Synthetic small molecule complement inhibitors. Curr Opin Investig Drugs 2004; 5: 1164-1173.
25. Morikis D, Floudas CA, Lambris JD. Structure-based integrative computational and experimental approach for the optimization of drug design. In: Sunderam VS, van Albada GD, Sloot PMA, Dongarra JJ, editors. ICCS 2005, Lecture notes in computer science: computational science. Berlin-Heidelberg: Springer-Verlag; 2005. pp 680-688.
26. Morikis D, Mallik B, Zhang L. Biophysical and bioengineering methods for the study of the complement system at atomic resolution. WSEAS Trans Biol Biomed 2006; 6: 408-413.
27. Bellows ML, Fung HK, Taylor MS, Floudas CA, López De Victoria A, Morikis D. New compstatin variants through two de novo protein design frameworks. Biophys J 2010; 98: 2337-2346.
28. Qu H, Magotti P, Ricklin D, Wu EL, Kourtzelis I, Wu Y-Q, Kaznessis YN, Lambris JD. Novel analogues of the therapeutic complement inhibitor compstatin with significantly improved affinity and potency. Mol Immunol, 48: 481-489.
29. López de Victoria A, Gorham RD, Jr, Bellows ML, Ling J, Lo DD, Floudas CA, Morikis DA. New generation of potent complement inhibitors of the compstatin family. Chem Biol Drug Des, 77: 431-440.
30. Sahu A, Morikis D, Lambris JD. Compstatin, a peptide inhibitor of complement, exhibits species-specific binding to complement component C3. Mol Immunol 2003; 39: 557-566.
31. Tamamis P, Morikis D, Floudas CA, Archontis G. Species specificity of the complement inhibitor compstatin investigated by all-atom molecular dynamics simulations. Proteins 2010; 5278: 2655-2667.
32. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, Valentin F, Wallace IM, Wilm A, Lopez R, Thompson JD, Gibson TJ, Higgins DG. ClustalW2 and ClustalX version 2. Bioinformatics 2007; 23: 2947-2948.
33. Davis ME, Madura JD, Luty BA, McCammon JA. Electrostatics and diffusion of molecules in solution: simulations with the University of Houston Brownian Dynamics Program. Comput Phys Commun 1991; 62: 187-197.
34. MacKerell ADJr, Bashford D, Bellott M, Dunbrack RLJr, Evanseck JD, Field MJ, Fischer S, Gao J, Guo H, Ha S, Joseph-McCarthy D, Kuchnir L, Kuczera K, Lau FTK, Mattos C, Michnick S, Ngo T, Nguyen DT, Prodhom B, Reiher WEIII, Roux B, Schlenkrich M, Smith JC, Stote R, Straub J, Watanabe M, Wiórkiewicz-Kuczera J, Yin D, Karplus M. An all-atom empirical potential for molecular modelling and dynamics study of proteins. J Phys Chem B 1998; 102: 3586-3616.
35. Mackerell AD, Jr, Feig M, Brooks CL, III. Extending the treatment of backbone energetics in protein force fields: limitations of gas-phase quantum mechanics in reproducing protein conformational distributions in molecular dynamics simulations. J Comput Chem 2004; 25: 1400-1415.
36. Macias AT, Mackerell AD, Jr. CH/pi interactions involving aromatic amino acids: refinement of the CHARMM tryptophan force field. J Comput Chem 2005; 26: 1452-1463.
37. Brooks BR, Brooks IIICL, Mackerell JrAD, Nilsson L, Petrella RJ, Roux B, Won Y, Archontis G, Bartels C, Boresch S, Caflisch A, Caves L, Cui Q, Dinner AR, Feig M, Fischer S, Gao J, Hodoscek M, Im W, Kuczera K, Lazaridis T, Ma J, Ovchinnikov V, Paci E, Pastor RW, Post CB, Pu JZ, Schaefer M, Tidor B, Venable RM, Woodcock HL, Wu X, Yang W, York DM, Karplus M. CHARMM: the biomolecular simulation program. J Comput Chem 2009; 30: 1545-1614.
38. Eswar N, Marti-Renom MA, Webb B, Madhusudhan MS, Eramian D, Shen M, Pieper U, Sali A. Comparative protein structure modeling with MODELLER. Curr Protoc Bioinformatics 2006;( Suppl 15): 5.6.1-5.6.30.
39. Krivov GG, Shapovalov MV, Dunbrack RL, Jr. Improved prediction of protein side-chain conformations with SCWRL4. Proteins 2009; 77: 778-795.
40. Seeber M, Cecchini M, Rao F, Settanni G, Caflisch A. Wordom: a program for efficient analysis of molecular dynamics simulations. Bioinformatics 2007; 23: 2625-2627.
41. Massova I, Kollman PA. Combined molecular mechanical and continuum solvent approach (MM-PBSA/GBSA) to predict ligand binding. Perspect Drug Discov Des 2000; 18: 113-135.
42. Im W, Lee MS, Brooks IIICL. Generalized born model with a simple smoothing function. J Comput Chem 2003; 24: 1691-1702.
43. Chen J, Im W, Brooks CL, III. Balancing solvation and intramolecular interactions: toward a consistent generalized born force field. J Am Chem Soc 2006; 128: 3728-3736.
44. Singh N, Warshel A. Absolute binding free energy calculations: on the accuracy of computational scoring of protein-ligand interactions. Proteins 2010; 78: 1705-1723.
45. Gilson MK, Zhou HX. Calculation of protein-ligand binding affinities. Annu Rev Biophys Biomol Struct 2007; 36: 21-42.
46. Swanson JMJ, Henchmann R, McCammon JA. Revisiting free energy calculations: a theoretical connection to MM/PBSA and direct calculation of the association free energy. Biophys J 2004; 86: 67-74.